N. Bräu

发表

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Stefan Zeuzem, Norman Gitlin, M. Buti, 2014, The New England journal of medicine.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

P. Sax, C. Stedman, D. Dieterich, 2015, The New England journal of medicine.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

O. Weiland, P. Thuluvath, G. Everson, 2014, Gut.

Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.

William M. Lee, E. Schiff, M. Shiffman, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatitis C pharmacotherapy clinic.

N. Bräu, E. Stone, H. B. Fung, 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

National Multicenter Study of HIV Testing and HIV Seropositivity in Patients With Chronic Hepatitis C Virus Infection

E. Bini, S. Currie, T. Wright, 2006, Journal of clinical gastroenterology.

Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area.

E. Bini, R. Eng, Sheldon T. Brown, 2002 .

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

E. Daar, K. Workowski, B. Doehle, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.

A. Mangia, M. Stepanova, L. Henry, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

V. de Lédinghen, P. Angus, K. Reddy, 2015, JAMA.

Fixed-Dose Combination TherapyWith Daclatasvir , Asunaprevir , and Beclabuvir for Noncirrhotic Patients With HCVGenotype 1 Infection

P. Angus, K. Reddy, B. Conway, 2015 .

Chronic Hepatitis C in Latinos: Natural History, Treatment Eligibility, Acceptance, and Outcomes

E. Bini, S. Ho, S. Currie, 2005, The American Journal of Gastroenterology.

Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection

E. Bini, M. Pedrosa, C. Hagedorn, 2005, The American Journal of Gastroenterology.

Treatment of chronic hepatitis C in HIV/HCV‐coinfection with interferon α‐2b+ full‐course vs. 16‐week delayed ribavirin

C. Giffen, J. Kostman, N. Bräu, 2004, Hepatology.

Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C

N. Bräu, 2004, Journal of viral hepatitis.

Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York city metropolitan area

E. Bini, R. Eng, Sheldon T. Brown, 2002, American Journal of Gastroenterology.

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

S. Pol, D. Nelson, M. Persico, 2017, The New England journal of medicine.

Black patients with chronic hepatitis C have a lower sustained viral response rate than non‐Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin *

E. Bini, M. Pedrosa, C. Hagedorn, 2006, Journal of viral hepatitis.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

T. Berg, T. Asselah, A. Mangia, 2015, The New England journal of medicine.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Brian L. Pearlman, T. Berg, T. Asselah, 2017, Gastroenterology.

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. Douglas, A. Malhotra, D. Skiest, 2021, The New England journal of medicine.

Acquired factor VIII inhibitor in patients with hepatitis C virus infection and the role of interferon‐α: A case report

N. Bräu, Z. Schreiber, 2005, American journal of hematology.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

I. Douglas, A. Malhotra, K. Blyth, 2022, eClinicalMedicine.

Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C.

E. Bini, N. Bräu, A. Aytaman, 2003, Journal of hepatology.

Clostridium difficile colitis after forced anal-receptive intercourse.

N. Bräu, E. Stone, H. B. Fung, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.

N. Bräu, 2005, Seminars in liver disease.

Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders

M. Kozal, M. Charafeddine, D. Cohen, 2019, Journal of medical virology.

A Randomized Trial of Pegylated Interferon α-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C

E. Bini, F. Klion, M. Russo, 2005, The American Journal of Gastroenterology.

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.

E. Bini, T. Hassanein, D. Dieterich, 2003 .

Editorial: a step forward in refining prognostication for patients with HIV‐associated hepatocellular carcinoma—Authors’ reply

D. Pinato, M. Bower, N. Bräu, 2018, Alimentary Pharmacology and Therapeutics.

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus–infected patients receiving ribavirin plus interferon alfa

E. Bini, T. Hassanein, D. Dieterich, 2003, American Journal of Gastroenterology.

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

P. Thuluvath, G. Everson, S. Pol, 2011 .

Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.

E. Bini, D. Dieterich, M. Sulkowski, 2005, Journal of acquired immune deficiency syndromes.

Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection

C. Tural, D. Cooper, D. Dieterich, 2007, AIDS.

Tuberculous abscesses in patients with AIDS.

N. Bräu, M. Simberkoff, P. Flomenberg, 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cardiac valve replacement in patients infected with the human immunodeficiency virus.

N. Bräu, R. Esposito, M. Simberkoff, 1992, The Annals of thoracic surgery.

Evaluation of the hepatitis C virus-infected patient: the initial encounter.

N. Bräu, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cutaneous protothecosis in a patient with AIDS and a severe functional neutrophil defect: successful therapy with amphotericin B.

N. Bräu, J. Bandres, W. Carey, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severe hepatitis in three AIDS patients treated with indinavir

D. Margolis, R. Wieczorek, N. Bräu, 1997, The Lancet.

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.

V. Soriano, A. Hatzakis, S. Pol, 2007, AIDS.

Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co‐infection: Clinically relevant or a diagnostic problem?

J. Rockstroh, F. Torriani, R. Solá, 2007, Journal of medical virology.

Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.

E. Bini, M. Sherman, J. Llovet, 2007, Journal of hepatology.

Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.

N. Bräu, 2005, The Journal of antimicrobial chemotherapy.

Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy

N. Bräu, 2003, AIDS.

Review article: adherence to medication for chronic hepatitis C – building on the model of human immunodeficiency virus antiretroviral adherence research

N. Bräu, J. Weiss, T. Swan, 2009, Alimentary pharmacology & therapeutics.

Progression to Cirrhosis in Latinos With Chronic Hepatitis C: Differences in Puerto Ricans With and Without Human Immunodeficiency Virus Coinfection and Along Gender

J. Rodríguez-Orengo, C. Ríos-Bedoya, N. Bräu, 2006, Journal of clinical gastroenterology.

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

J. Rodríguez-Orengo, C. Ríos-Bedoya, M. Salvatore, 2006, Journal of hepatology.

Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin

D. Dieterich, N. Bräu, J. Weiss, 2017, Journal of NeuroVirology.

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse.

S. Asch, A. Gifford, M. Sklar, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study

E. Daar, K. Workowski, B. Doehle, 2016 .

HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status.

J. Roy, A. Justice, M. Kallan, 2019, Journal of the National Cancer Institute.

Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma

R. Homer, A. Justice, M. Kallan, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Ulysses Diva, Vinod K Rustgi, P. Thuluvath, 2012, The Lancet. Infectious diseases.

Once-weekly recombinant human erythropoetin (Epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV)-infected patients receiving interferon-α-2b (IFN)/RBV combination therapy

E. Bini, T. Hassanein, D. Dieterich, 2001 .

Renal Toxicity of Long-Term Therapy With Tenofovir in HIV-Infected Patients

N. Bräu, H. B. Fung, M. Monteagudo-Chu, 2012, Journal of pharmacy practice.

Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study.

M. Zoli, E. Giannini, F. Farinati, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The albumin‐bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV‐associated hepatocellular carcinoma

D. Pinato, M. Nelson, B. Mínguez, 2018, Alimentary pharmacology & therapeutics.

FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients

A. Justice, D. Rimland, M. Goetz, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Group C Streptococcus dysgalactiae subsp.equisimilis (SDSE) Endocarditis with Endogenous Endophthalmitis and Aortic Root Abscess

N. Bräu, L. Yung, M. Rashid, 2019, IDCases.

Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation

J. Gorman, D. Dieterich, S. Marcus, 2018, International journal of psychiatry in medicine.

Decline in haemoglobin A1c values in diabetic patients receiving interferon‐alpha and ribavirin for chronic hepatitis C *

A. Rosman, P. Greenberg, N. Bräu, 2006, Journal of viral hepatitis.

Increasing antiviral treatment through integrated hepatitis C care: a randomized multicenter trial.

M. Sklar, S. Ho, E. Groessl, 2013, Contemporary clinical trials.

Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

V. Mazzaferro, J. Miro, A. Forner, 2020, JHEP reports : innovation in hepatology.

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

John Hornberger, Francesca J Torriani, J. Hornberger, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Impact of Hepatitis C Treatment Initiation on Adherence to Concomitant Medications

S. Marcus, Maria Pizzirusso, N. Bräu, 2014, The Journal of the Association of Nurses in AIDS Care : JANAC.

Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.

A. Justice, M. Kallan, T. Taddei, 2020, Journal of acquired immune deficiency syndromes.

Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes

T. Asselah, M. Stepanova, L. Henry, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to inferferon monotherapy or combination therapy, and in combination therapy relapsers

E. Bini, F. Klion, M. Russo, 2001 .

Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.

C. Rentsch, A. Justice, T. Taddei, 2021, Journal of hepatology.

Clinical Implications of Hepatic Steatosis in Patients with Chronic Hepatitis C: A Multicenter Study of U.S. Veterans

E. Bini, S. Ho, S. Currie, 2007, Digestive Diseases and Sciences.